First Manhattan’s Royalty Pharma RPRX Stock Holding History

First Manhattan’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,500	Closed	-$106K	–	1165
2024 Q1	$106K	Sell	3,500 -5	-0.1%	-$147	﹤0.01%	759
2023 Q4	$98.5K	Buy	3,505 +5	+0.1%	+$137	﹤0.01%	759
2023 Q3	$95K	Hold	3,500	–	–	﹤0.01%	769
2023 Q2	$108K	Hold	3,500	–	–	﹤0.01%	751
2023 Q1	$126K	Sell	3,500 -200	-5%	-$7.42K	﹤0.01%	760
2022 Q4	$146K	Hold	3,700	–	–	﹤0.01%	759
2022 Q3	$148K	Hold	3,700	–	–	﹤0.01%	742
2022 Q2	$155K	Hold	3,700	–	–	﹤0.01%	758
2022 Q1	$144K	Hold	3,700	–	–	﹤0.01%	816
2021 Q4	$147K	Hold	3,700	–	–	﹤0.01%	806
2021 Q3	$133K	Hold	3,700	–	–	﹤0.01%	817
2021 Q2	$151K	Hold	3,700	–	–	﹤0.01%	784
2021 Q1	$161K	Buy	3,700 +200	+6%	+$9.48K	﹤0.01%	745
2020 Q4	$175K	Buy	+3,500	New	+$148K	﹤0.01%	684

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

First Manhattan's RPRX Position: Q2 2024 in Review

First Manhattan sold out of Royalty Pharma (RPRX) in Q2 2024, closing a stake of 3,500 shares — an estimated $106K sold.

First Manhattan first reported a position in RPRX in Q4 2020 and held it in 14 quarters. The position peaked at $175K in Q4 2020. 378 funds tracked by Wall St. Rank hold RPRX as of Q2 2024.

First Manhattan reported no remaining Royalty Pharma position as of Q2 2024 after selling out during the quarter.
First Manhattan sold 3,500 Royalty Pharma shares in Q2 2024, an estimated $106K.
First Manhattan first reported a position in Royalty Pharma in Q4 2020 and held it in 14 quarters.
First Manhattan's Royalty Pharma position peaked at $175K in Q4 2020.
378 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.